Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Suburban Research Associates

Neither a doctor nor a teaching hospital

Research payments

$1,541,931

133 payments

Through program year 2025, Suburban Research Associates is reported as receiving $1,541,931 in research payments, across 133 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $142,372 26
2024 Research $93,391 9
2023 Research $10,409 6
2022 Research $282,581 41
2021 Research $574,064 31
2020 Research $398,446 11
2019 Research $40,667 9

Breakdown

Who paid Research payments · program years 2019–2025
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $1,126,975 12 payments
  2. Eli Lilly and Company $117,114 9 payments
  3. ITI, Inc. $65,977 11 payments
  4. AbbVie, Inc. $37,923 6 payments
  5. Corcept Therapeutics $37,554 13 payments
  6. Avanir Pharmaceuticals, Inc. $36,661 24 payments
  7. Vertex Pharmaceuticals Incorporated $24,440 1 payment
  8. Novo Nordisk AS $22,498 12 payments
  9. ACADIA Pharmaceuticals Inc $16,454 6 payments
  10. Biohaven Pharmaceutical Holding Company Ltd. $16,139 12 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole As Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder. $752,757 7 payments
  2. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $326,480 3 payments
  3. A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder Who Have an Inadequate Response to Generalized Anxiety Disorder Treatment $65,977 11 payments
  4. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of Tirzepatide Once Weekly Compared to Placebo in Adult Participants With Type 1 Diabetes and Obesity Or Overweight (Surpass-T1d-1) $59,897 1 payment
  5. A Study of Ly3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain $49,915 4 payments
  6. Brexpiprazole as Combination Therapy With Sertraline in the Treatment of Adults With Post-traumatic Stress Disorder $43,232 1 payment
  7. 18-Avp-786-207 $36,661 24 payments
  8. Cort118335-876 $28,304 10 payments
  9. A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy $24,440 1 payment
  10. Nn6535-4725 $22,498 12 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record